Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis

Tiniakos, 2010, Nonalcoholic fatty liver disease: pathology and pathogenesis, Annu Rev Pathol, 5, 145, 10.1146/annurev-pathol-121808-102132 Corrado, 2014, Review of treatment options for nonalcoholic fatty liver disease, Med Clin North Am, 98, 55, 10.1016/j.mcna.2013.09.001 Pacifico, 2011, Management of metabolic syndrome in children and adolescents, Nutr Metab Cardiovasc Dis, 21, 455, 10.1016/j.numecd.2011.01.011 Italian Association for the Study of the Liver (AISF), 2017, AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions, Dig Liver Dis, 49, 471, 10.1016/j.dld.2017.01.147 European Association for the Study of the Liver (EASL), 2016, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, Diabetologia, 59, 1121, 10.1007/s00125-016-3902-y Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 Targher, 2018, Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus, Nat Rev Endocrinol, 14, 99, 10.1038/nrendo.2017.173 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Singh, 2017, Treatment options for alcoholic and non-alcoholic fatty liver disease: a review, World J Gastroenterol, 23, 6549, 10.3748/wjg.v23.i36.6549 Orci, 2016, Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression, Clin Gastroenterol Hepatol, 14, 1398, 10.1016/j.cgh.2016.04.036 Hannah, 2016, Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease, Dig Dis Sci, 61, 1365, 10.1007/s10620-016-4153-y Zelber-Sagi, 2016, Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials, Therap Adv Gastroenterol, 9, 392, 10.1177/1756283X16638830 Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 Yuan, 2015, Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles, J Transl Med, 13, 24, 10.1186/s12967-015-0383-6 Sun, 2018, Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21, Br J Pharmacol, 175, 374, 10.1111/bph.14079 Kong, 2004, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nat Med, 10, 1344, 10.1038/nm1135 Chang, 2010, Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, J Lipid Res, 51, 2504, 10.1194/jlr.M001958 Lee, 2006, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, Diabetes, 55, 2256, 10.2337/db06-0006 Zhu, 2019, Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway, Free Radical Biol Med, 141, 192, 10.1016/j.freeradbiomed.2019.06.019 Zhao L, Chen Y, Tang R, Chen Y, Li Q, Gong J, et al. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J Gastroenterol Hepatol 2011; 26(5): 875–83. van den Boomen, 2020, Ubiquitin-mediated regulation of sterol homeostasis, Curr Opin Cell Biol, 65, 103, 10.1016/j.ceb.2020.04.010 Li, 2009, Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine, J Biol Chem, 284, 28885, 10.1074/jbc.M109.052407 Bedalov, 2016, Biology, chemistry, and pharmacology of sirtuins, Methods Enzymol, 574, 183, 10.1016/bs.mie.2016.03.011 Klotz, 2015, Redox regulation of FoxO transcription factors, Redox Biol, 6, 51, 10.1016/j.redox.2015.06.019 Li, 2017, A global perspective on FoxO1 in lipid metabolism and lipid-related diseases, Prog Lipid Res, 66, 42, 10.1016/j.plipres.2017.04.002 Sin, 2015, Modulation of SIRT1-FoxO1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance, Cell Physiol Biochem, 35, 541, 10.1159/000369718 Qiang, 2010, Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization, J Biol Chem, 285, 27396, 10.1074/jbc.M110.140228 Guo, 2019, Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol, Cell Res, 29, 151, 10.1038/s41422-018-0123-6 Chen, 2012, Cytotoxicity and antihyperglycemic effect of minor constituents from Rhizoma Coptis in HepG2 cells, Fitoterapia, 83, 67, 10.1016/j.fitote.2011.09.014 Gómez-Lechón, 2007, A human hepatocellular in vitro model to investigate steatosis, Chem Biol Interact, 165, 106, 10.1016/j.cbi.2006.11.004 Napper, 2005, Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1, J Med Chem, 48, 8045, 10.1021/jm050522v He J, Zhang A, Song Z, Guo S, Chen Y, Liu Z, et al. The resistant effect of SIRT1 in oxidative stress-induced senescence of rat nucleus pulposus cell is regulated by Akt-FoxO1 pathway. Biosci Rep 2019; 39(5): BSR20190112. Lammi C, Zanoni C, Scigliuolo GM, D’Amato A, Arnoldi A. Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2 cell line. J Agric Food Chem 2014; 62(29): 7151–9. Fon Tacer, 2011, Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation, J Lipids, 2011, 10.1155/2011/783976 Goldstein, 2002, Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis, Arch Biochem Biophys, 397, 139, 10.1006/abbi.2001.2615 van der Wulp, 2013, Regulation of cholesterol homeostasis, Mol Cell Endocrinol, 368, 1, 10.1016/j.mce.2012.06.007 Goedeke, 2012, Regulation of cholesterol homeostasis, Cell Mol Life Sci, 69, 915, 10.1007/s00018-011-0857-5 Brown, 1997, The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor, Cell, 89, 331, 10.1016/S0092-8674(00)80213-5 Zhao, 2017, Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease, BMC Endocr Disord, 17, 13, 10.1186/s12902-017-0165-7 Yan, 2015, Efficacy of berberine in patients with non-alcoholic fatty liver disease, PLoS ONE, 10, e0134172, 10.1371/journal.pone.0134172 Chang, 2016, Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease, J Transl Med, 14, 266, 10.1186/s12967-016-0982-x Li, 2016, Berberine alleviates olanzapine-induced adipogenesis via the AMPKα-SREBP pathway in 3T3-L1 cells, Int J Mol Sci, 17, 1865, 10.3390/ijms17111865